Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab

Inclusion Criteria: * Age 18 years or older. * Patient scheduled to start an epidermal growth factor receptor inhibitor (must be one of these three: panitumumab, erlotinib, cetuximab) within the next 3 days or patient has already started the epidermal growth factor receptor inhibitor but has not been on it for longer than 3 days and has no signs or symptoms potentially suggestive of EGFR inhibitor toxicity. * Ability to reliably apply Menadione Topical Lotion / placebo twice a day to the face. * Ability to complete questionnaire(s) by themselves or with assistance. * Negative pregnancy test (serum or urine) done ≤ 7 days prior to registration, for women of childbearing potential only. * Willing to have photographs taken to assess rash. Exclusion Criteria: * Any active facial and/or chest rash, including adult acne, at the time of randomization. * Cutaneous metastases, skin cancer, or a history of precancerous skin lesions involving the face and/or chest. * Use of topical corticosteroids on the face and/or chest at the time of study entry or their anticipated use in the next 8 weeks. * Any type of ongoing therapy for rash. * Any of the following: * Pregnant women * Nursing women * Men or women of childbearing potential who are unwilling to employ adequate contraception since this study involves agents that have known genotoxic, mutagenic and teratogenic effects * Use of any antibiotic at the time of study or their anticipated use in the 8 weeks immediately following …